Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival (2013)

Peer-Reviewed Study · Troger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M · December 2013

Troger W et al., 2013-12: Open-label randomised trial in 220 patients with locally advanced or metastatic pancreatic cancer: Viscum album extract plus best supportive care gave median survival of 4.8 versus 2.7 months against no antineoplastic therapy.

Median OS was 4.8 for VaL and 2.7 months for control patients (prognosis-adjusted hazard ratio, HR=0.49; p<0.0001). Within the 'good' prognosis subgroup, median OS was 6.6 versus 3.2 months (HR=0.43; p<0.0001), within the 'poor' prognosis subgroup, it was 3.4 versus 2.0 months respectively (HR=0.55; p=0.0031).

Abstract, Findings

Troger W et al., 2013-12: Open-label randomised trial in 220 patients with locally advanced or metastatic pancreatic cancer: Viscum album extract plus best supportive care gave median survival of 4.8 versus 2.7 months against no antineoplastic therapy. Study type: randomized trial.